Immunotherapy for brain tumors with DNA repair problems
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a combination of two immunotherapy drugs, relatlimab and nivolumab, for people with certain brain tumors (high-grade glioma or DIPG) that have DNA repair issues. The treatment aims to help the immune system fight the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 39 years old.
- You weigh at least 40 kg (if in the US) or 30 kg (if elsewhere).
- You have a newly diagnosed high-grade glioma or DIPG that has been confirmed by biopsy.
- Your tumor shows signs of DNA repair deficiency (your doctor will check this).
- You have already received radiation therapy as part of your initial treatment.
- You are generally in good health with adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new immunotherapy (nivolumab) for children, teens, and young adults with a specific type of aggressive brain tumor (glioblastoma that has a DNA repair problem). It aims to see if giving this treatment early, right after surgery, can help the immune system fight the tumor.
This trial tests a combination of two oral medications, olutasidenib and temozolomide, for people with a specific type of aggressive brain tumor (high-grade glioma) that has an IDH1 mutation. The goal is to see if this combination can help control the tumor after standard treatment like radiation.
This study tests a combination of three treatments for newly diagnosed high-grade glioma: a drug called ADI-PEG 20, chemotherapy (temozolomide), and radiation therapy. The goal is to see if this combination is safe and effective for children and young adults with this type of brain or spinal cord tumor.
This trial tests a drug called tovorafenib for children and young adults with certain types of brain tumors that have specific genetic changes. It is aimed at helping people who have just finished radiation therapy.
This early-phase trial tests a customized vaccine (made from your tumor’s cell parts) along with an immune “checkpoint blocker” medicine. It’s for newly diagnosed DIPG/DMG to see if this combination is safe and can help control the cancer.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
Hear when a new High Grade Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.